1 Department of Bioengineering, University of California, Los Angeles, California.
2 Center for Minimally Invasive Therapeutics (C-MIT), University of California, Los Angeles, California.
Tissue Eng Part A. 2019 May;25(9-10):679-687. doi: 10.1089/ten.TEA.2019.0032.
In this Perspective, we discuss the impact of the past 25 years of tissue engineering on the development of clinical therapies. Based on their success and other significant research accomplishments, platforms of innovation were identified. Their discoveries will enable tissue engineering inspired therapies to meet the requirements necessary for large-scale manufacturing and Food and Drug Administration (FDA) approval for a diverse range of indications.
在本观点中，我们讨论了过去 25 年组织工程对临床治疗发展的影响。基于它们的成功和其他重要的研究成果，确定了创新平台。它们的发现将使组织工程灵感的治疗方法能够满足大规模制造和美国食品和药物管理局（FDA）批准各种适应症的要求。
